Evaluation of disease activity, disability and quality of life in patients with persistently active refractory juvenile idiopathic (chronic) arthritis (JIA) treated with monoclonal anti-tumor necrosis factor-α antibody (Infliximab)

被引：0
|
作者：
Gerloni, V
Pontikaki, I
Desiati, F
Lupi, E
Gattinara, M
Fantini, F
机构：
[1] Univ Milan, Chair Rheumatol, I-20122 Milan, Italy
[2] Gaetano Pini Inst, Ctr Rheumat Children, Milan, Italy
来源：
JOURNAL OF RHEUMATOLOGY | 2001年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
T110
引用
收藏
页码：67 / 67
页数：1
相关论文
共 42 条
  • [1] Evaluation of disease activity, disability and quality of life in patients with persistently active refractory juvenile chronic arthritis after one year treatment with monoclonal anti-tumor necrosis factor-α antibody (Infliximab).
    Gerloni, V
    Pontikaki, I
    Desiati, F
    Lupi, E
    Gattinara, M
    Fantini, F
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S80 - S80
  • [2] Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor a monoclonal antibody, infliximab, in persistently active refractory juvenile idiopathic (chronic) arthritis
    Gerloni, V
    Pontikaki, I
    Lurati, A
    Demarco, G
    Fantini, F
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 286 - 286
  • [3] Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis
    Norambuena, X.
    Mallol, J.
    Rios, G.
    Quevedo, F.
    Quezada, A.
    [J]. ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2007, 35 (02) : 52 - 56
  • [4] Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor α monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis -: Results of an open-label prospective study
    Gerloni, V
    Pontikaki, I
    Gattinara, M
    Desiati, F
    Lupi, E
    Lurati, A
    Salmaso, A
    Fantini, F
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 548 - 553
  • [5] Ghrelin levels in patients with juvenile idiopathic arthritis: relation to anti-tumor necrosis factor treatment and disease activity
    Karagiozoglou-Lampoudi, Thomais
    Trachana, Maria
    Agakidis, Charalampos
    Pratsidou-Gertsi, Polyxeni
    Taparkou, Anna
    Lampoudi, Sotiria
    Kanakoudi-Tsakalidou, Florentia
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (10): : 1359 - 1362
  • [6] Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis
    Antoni, C
    Kalden, JR
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1999, 17 (06) : S73 - S77
  • [7] Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents
    Russo, Ricardo A. G.
    Katsicas, Maria M.
    [J]. JOURNAL OF RHEUMATOLOGY, 2009, 36 (05) : 1078 - 1082
  • [8] Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-α Human Monoclonal Antibody, in Patients With Psoriatic Arthritis
    Xu, Zhenhua
    Vu, Thuy
    Lee, Howard
    Hu, Chuanpu
    Ling, Jie
    Yan, Hong
    Baker, Daniel
    Beutler, Anna
    Pendley, Charles
    Wagner, Carrie
    Davis, Hugh M.
    Zhou, Honghui
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1056 - 1070
  • [9] Pilot study of chimeric monoclonal anti-tumor necrosis factor alpha anti-body (infliximab) with methotrexate in polyarticular juvenile idiopathic arthritis
    Chaturvedi, VP
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (12): : 3421 - 3421
  • [10] Population pharmacokinetics of golumumab.: A human anti-tumor necrosis factor-α monoclonal antibody, in patients with psoriatic arthritis
    Xu, Z.
    Vu, T.
    Lee, H.
    Ling, J.
    Hu, C.
    Baker, D.
    Beutler, A.
    Pendley, C.
    Wagner, C. I.
    Davis, H. M.
    Zhou, H.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1112 - 1112
12345